Strictly Buy and Sell Set Ups Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Strictly Buy and Sell Set Ups

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: - with a K	2/22/2005 11:13:12 AM
	Read Replies (2) of 13449

Former pick IPXL moving strongly today. Looks like speculation is building as a takeover target, what BAC mentioned in their January upgrade. If the price holds above $18 for a few days this could be real interesting. I'm long. stockcharts.com[h,a]daclyiay[pc21!d10,1!f][vc60][iut!Lg!Lah12,26,9]&pref=G Yahoo post: nvs deal by: drugdok (35/M/CA) Long-Term Sentiment: Buy 02/21/05 10:32 pm Msg: 7589 of 7593 IMO...The NVS deal to buy elab could only be good for IPXL due to the fact that there are not many generics that elab and ipxl compete with each other on. Having said that, the big rumor that brought ipxl down a few months a ago, was that sandoz/nvs had an application for the generic wellbutrin sr 100/150 filed. Even if that is true now, Ipxl looks like they will not have any significant new competition for the wellbutrin sr franchise in the near future (since elab is now nvs). Further, consolidation is a must for generics in 2005, and IPXL is a ripe cherry waiting to be picked. Long and strong.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next